

CLINICAL DEVELOPMENT SOLUTIONS TO IMPROVE HUNTINGTON'S DISEASE RESEARCH



New and better disease-modifying treatments for Huntington's disease (HD) are on the horizon, but effort remains in the quest to improve clinical research outcomes. Leverage Signant's SmartSignals end-to-end solutions as well as our in-house expertise in rare CNS disorders to address research challenges.

IMPROVE RATINGS ACCURACY

Endpoints in HD studies rely on UHDRS and other ClinROs, but inconsistencies in assessment scoring and administration can lead to difficulties interpreting the data collected. Signant's Rater Training program focuses on standardizing assessment technique and reducing inter- and intra-rater variability. We also create custom training tailored to the individual needs of each study for use across sites and programs.

PARTNER WITH HD EXPERTS

From consulting on outcome measure selection and implementation to reducing burdens on sites and patients, Signant's in-house experts will help you navigate common HD challenges throughout the study lifecycle. Talk through your protocol with our rare disease and CNS experts experienced in HD studies.

INCREASE OPERATIONAL EFFICIENCY

Conducting studies in multiple countries and across many sites introduces logistical challenges that can be the source of errors or delays. Study teams trust our RTSM system to not only launch studies faster but to handle complex cohorting, study supply forecasting, and data transfers with efficiency and accuracy.

MAKE IT EASIER TO PARTICIPATE

Simplify the clinical trial experience for patients and sites alike by providing tools like eConsent and Telemedicine. These solutions help reduce unnecessary site visits, improve remote collaboration between sites and patients, and ensure protocol adherence.

ENSURE ENDPOINT RELIABILITY

Guide investigative staff through proper ClinRO assessment technique using our enhanced clinician ratings platform. Automated scoring as well as built-in edit checks help reduce errors. When paired with PureSignal Analytics, we can proactively monitor COA data in real-time, creating opportunities to mitigate risks before they impact your signal detection.


DIGITALIZE THE PROCESS

Each solution and service within our SmartSignals evidence generation platform can be applied to a study independently. However, when combined, they create an intuitive and powerful digital ecosystem for creating and managing complex global studies. Plus, every study is supported by a dedicated team of clinical science and operations experts.




At Signant, our focus is helping you develop and deliver treatments or therapies faster in order to improve the quality of life for Huntington's disease patients everywhere.

SIGNANT'S HUNTINGTON'S DISEASE CLINICAL TRIAL EXPERIENCE



SMARTSIGNALS SOLUTIONS


The SmartSignals solutions can be used individually or integrated together for a seamless, end-to-end digital experience.



DISCUSS YOUR NEXT STUDY WITH US

Our global team of therapeutic area experts advise on all areas of the clinical development process, including:

- Clinical science and medicine
- Data analysis
- Regulatory
- Operations and trial administration
- Global logistics



MEET THE EXPERTS